Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Follow-up of Subjects With Childhood Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Trial Profile

Long-term Follow-up of Subjects With Childhood Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elivaldogene-tavalentivec (Primary)
  • Indications Adrenoleucodystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Sep 2019 According to a bluebird bio Media release, as of February 11, 2019, 47 patients who had undergone allo-HSCT were enrolled in this study.
    • 18 Sep 2019 Results presented in a bluebird bio Media Release
    • 18 Sep 2019 According to a bluebird bio Media release, data were presented at the 13th European Pediatric Neurology Society (EPNS) Congress in Athens, Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top